Exelixis to slash 160 jobs as prostate cancer trial fails

September 2, 2014 1:11 PM

6 0

Exelixis to slash 160 jobs as prostate cancer trial fails

Send this story to a friend

Once high-flying Exelixis Inc. will cut about 160 jobs after disclosing that its drug Cometriq failed a late-stage trial against a type of prostate cancer.

Also read: Chemours stock and bonds rally as DuPont splits settlement of toxic chemical suits

Read more

To category page

Loading...